Sandoz bags US epinephrine
Sandoz has acquired exclusive distribution and commercialisation rights in the US to Adamis Pharamceuticals’ Symjepi (epinephrine) subcutaneous injectable, a non-substitutable alternative to Mylan’s EpiPen anaphylaxis treatment. The deal covers both an approved 0.3mg strength as well as a 0.15mg version that is pending US Food and Drug Administration (FDA) approval, while Sandoz also has “first right of negotiation” to acquire commercial rights outside of the US.
You may also be interested in...
Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Are nanoparticle data necessarily relevant to every ingredient assessment undertaken by Cosmetic Ingredient Review’s independent expert panel? Let us be the judge of that, the panel said on 27 September at its 162nd meeting.
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.